Abstract
The recent approval of liraglutide, lorcaserin, naltrexone/bupropion extended-release, and phentermine/topiramate extended-release, brings the number of medications for long-term weight loss to 5 (including orlistat). Indicated for the treatment of patients with overweight (body mass index [BMI] ≥27 kg/m2 with ≥1 weight-related comorbidity) or obesity (BMI ≥30 kg/m2), these medications provide new opportunities to address this burgeoning health problem.
MeSH terms
-
Anti-Obesity Agents / administration & dosage*
-
Anti-Obesity Agents / adverse effects
-
Benzazepines / administration & dosage
-
Body Mass Index
-
Bupropion / administration & dosage
-
Guidelines as Topic
-
Humans
-
Lactones / administration & dosage
-
Life Style*
-
Liraglutide / administration & dosage
-
Naltrexone / administration & dosage
-
Obesity / drug therapy*
-
Obesity / therapy
-
Orlistat
-
Overweight / drug therapy
-
Phentermine / administration & dosage
-
Primary Health Care*
-
Risk Factors
-
Treatment Outcome
-
Weight Loss / drug effects*
Substances
-
Anti-Obesity Agents
-
Benzazepines
-
Lactones
-
Bupropion
-
Naltrexone
-
lorcaserin
-
Liraglutide
-
Orlistat
-
Phentermine